---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-008306"
form_type: "8-K"
ticker: "SHPH"
cik: "0001757499"
company_name: "Shuttle Pharmaceuticals Holdings, Inc."
filed_at: "2025-02-26T23:59:59+00:00"
generated_at: "2026-05-26T03:49:50.603291+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Shuttle Pharma corporate update: Phase 2 glioblastoma trial 40% enrolled; no financial results

## Summary
- Phase 2 trial of Ropidoxuridine for glioblastoma: 17 of 40 initial patients enrolled (40%), 8 completed all 7 cycles.
- Trial conducted at Georgetown, Allegheny Health Network, UNC, UVA, Hackensack, Miami Cancer Institute.
- Diagnostics subsidiary entered sponsored research agreement with UCSF to develop PSMA ligand as theranostic.
- CEO Dr. Anatoly Dritschilo invested $237,500 along with other investors in recent financing.
- Launched new corporate website highlighting dual approach to cancer therapeutics and diagnostics.

## SEC filing metadata
- accession: 0001493152-25-008306
- form_type: 8-K
- ticker: SHPH
- cik: 0001757499
- company_name: Shuttle Pharmaceuticals Holdings, Inc.
- filed_at: 2025-02-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1757499/000149315225008306/0001493152-25-008306-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1757499/000149315225008306/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-008306
- JSON: https://secwatch.observer/filing/0001493152-25-008306.json
- Plain text: https://secwatch.observer/filing/0001493152-25-008306.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.